Context Therapeutics appoints Jennifer Minai-Azary as CFO with $365K base salary

Context Therapeutics Inc.

Jennifer Minai-Azary appointed CFO; previously CFO at Millendo Therapeutics, led merger with Tempest.
Employment agreement: $365,000 annual base salary; target annual bonus of 40% of base salary.
Granted non-qualified stock options for 52,753 shares, vesting monthly over 3 years.
Severance: 9 months base salary if terminated without cause; change-in-control triggers 12 months salary plus full equity vesting.
Press release also notes Alex Levit was appointed Chief Legal Officer in April 2021.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Minai-Azary

Chief Financial Officer

CNTX · Context Therapeutics Inc.

Effective: 2021-11-01
Filed: November 1, 2021, 7:59 PM ET

On November 1, 2021, Context Therapeutics Inc. (the “Company”) appointed Jennifer Minai-Azary as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jennifer Minai-Azary was appointed as Chief Financial Officer at Context Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 1, 2021, Context Therapeutics Inc. (the “Company”) appointed Jennifer Minai-Azary as the Company’s Chief Financial Officer.

View on SEC.gov

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-21-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.